Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report 2026

The vesicular monoamine transporter 2 (vmat2) inhibitor market size has grown rapidly in recent years. It will grow from $1.25 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to approval of tetrabenazine, rising antipsychotic usage, increased movement disorder diagnosis, hospital-based neurology care, limited alternative therapies.

The vesicular monoamine transporter 2 (vmat2) inhibitor market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growing tardive dyskinesia prevalence, expansion of deutetrabenazine usage, rising neurological disorder awareness, growth of specialty neurology clinics, increased oral drug preference. Major trends in the forecast period include rising use of targeted neurotransmitter modulation, increasing treatment of tardive dyskinesia, expansion of oral neurological therapies, growing focus on movement disorder management, increased adoption of long-term neurology drugs.

The rising prevalence of Parkinson’s disease is anticipated to drive the expansion of the vesicular monoamine transporter 2 (VMAT2) inhibitor market in the coming years. Parkinson's disease is a progressive neurological disorder that impacts movement due to the degeneration of dopamine-producing cells in the brain. The growing prevalence of Parkinson's disease is primarily attributed to an aging population, improved diagnostic methods, environmental factors such as exposure to toxins, genetic predispositions, and heightened awareness of the condition. VMAT2 inhibitors assist in managing Parkinson's symptoms by regulating dopamine release and alleviating tremors and dyskinesia. For example, in October 2025, Parkinson's UK, a UK-based research and support charity, reported that by 2030, Parkinson’s cases in the UK are expected to reach 173,000, with approximately 28,000 new diagnoses projected in 2025, equating to one new diagnosis every 20 minutes as the population ages and grows. Consequently, the increasing prevalence of Parkinson’s disease is fueling growth in the vesicular monoamine transporter 2 (VMAT2) inhibitor market.

Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitors market are concentrating on developing novel formulations such as capsules to boost patient adherence, enhance drug stability, and optimize therapeutic outcomes. Capsules, a solid dosage form contained within a gelatin or HPMC shell, assist VMAT2 inhibitors by maintaining drug stability, ensuring accurate dosing, and improving patient compliance. For example, in July 2024, Neurocrine Biosciences Inc., a US-based biopharmaceutical firm, introduced Ingrezza Sprinkle (valbenazine) capsules, a new formulation of the VMAT2 inhibitor Ingrezza created to simplify administration for adults with tardive dyskinesia and chorea associated with Huntington's disease who face dysphagia or difficulty swallowing. Ingrezza Sprinkle provides the same effective dosing options as Ingrezza and can be taken either by sprinkling the capsule contents onto soft food or by swallowing the capsule whole.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. Through this acquisition, Bristol Myers Squibb aims to enhance its neurology portfolio by gaining access to Karuna Therapeutics' promising pipeline of innovative therapies, including the VMAT2 inhibitor KarXT, which has the potential to address unmet needs in psychiatric disorders such as schizophrenia, thereby broadening its therapeutic offerings and accelerating growth in the neuroscience sector. Karuna Therapeutics is a US-based biopharmaceutical company that develops vesicular monoamine transporter 2 (VMAT2) inhibitor treatments.

Major companies operating in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Neurocrine Biosciences Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Bausch Health Companies Inc., Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen Inc.

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2025. The regions covered in the vesicular monoamine transporter 2 (vmat2) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vesicular monoamine transporter 2 (vmat2) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised the cost of imported neurological APIs used in the manufacturing of oral VMAT2 inhibitor therapies. These impacts are most evident in Europe and Asia Pacific, where producers rely on cross border sourcing for specialty neurological inputs. Rising tariff related expenses have influenced production costs, pricing strategies, and availability of oral VMAT2 inhibitor drugs. This has affected procurement planning across hospital and retail pharmacy channels. Positively, tariffs are encouraging domestic synthesis of specialty neurological drugs, expanded local manufacturing capacity, and stronger long term supply resilience.

The vesicular monoamine transporter 2 (vmat2) inhibitor market research report is one of a series of new reports that provides vesicular monoamine transporter 2 (vmat2) inhibitor market statistics, including vesicular monoamine transporter 2 (vmat2) inhibitor industry global market size, regional shares, competitors with a vesicular monoamine transporter 2 (vmat2) inhibitor market share, detailed vesicular monoamine transporter 2 (vmat2) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vesicular monoamine transporter 2 (vmat2) inhibitor industry. This vesicular monoamine transporter 2 (vmat2) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a medication that inhibits VMAT2, a protein responsible for moving monoamines (dopamine, serotonin, norepinephrine) into synaptic vesicles for release in the brain. VMAT2 inhibitors are used to manage neurological and psychiatric conditions by decreasing excessive neurotransmitter release, especially dopamine, to treat disorders such as tardive dyskinesia, Huntington’s disease, and other hyperkinetic movement disorders.

The key drugs in the vesicular monoamine transporter 2 (VMAT2) inhibitor category include tetrabenazine, deutetrabenazine, valbenazine, and other related compounds. Tetrabenazine is a VMAT2 inhibitor that helps manage movement disorders by lowering dopamine levels in the brain. These medications are delivered through various routes, such as oral administration and other methods, and are distributed via hospital pharmacies, online pharmacies, and retail pharmacies. They are prescribed for multiple applications, including Huntington’s disease, tardive dyskinesia, and other disorders. The main end users of these medications include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market consists of sales of products such as deutetrabenazine, valbenazine, and tetrabenazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.